About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 748178, 9 pages
http://dx.doi.org/10.1155/2013/748178
Review Article

Cancer Morbidity in Rheumatoid Arthritis: Role of Estrogen Metabolites

1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha 641, Saudi Arabia
2Institute of Infection and Immunity, Cardiff University School of Medicine, Henry Wellcome Building, Heath Park, Cardiff CF14 4XN, UK

Received 24 April 2013; Accepted 17 August 2013

Academic Editor: Shigeru Kotake

Copyright © 2013 Wahid Ali Khan and Mohd Wajid Ali Khan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Worthington, “Investigating the genetic basis of susceptibility to rheumatoid arthritis,” Journal of Autoimmunity, vol. 25, pp. 16–20, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Kinlen, “Immuno suppression and cancer,” in Mechanism of Carcinogenesis in Risk Identification, H. Vainio, P. Magee, D. McGregor, and A. McMicheal, Eds., pp. 237–253, International Agency for Research on Cancer, Lyon, France, 1992.
  3. D. P. M. Symmons, “Lymphoma and rheumatoid arthritis—again,” Rheumatology, vol. 46, no. 1, pp. 1–2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Prior, D. P. M. Symmons, and C. F. Hawkins, “Cancer morbidity in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 43, no. 2, pp. 128–131, 1984. View at Scopus
  5. S. H. Swerdlov, E. Campo, N. L. Harris, et al., WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue, International Agency for Research on Cancer, Lyon, France, 2008.
  6. S. Y. Kristinsson, L. R. Goldin, M. Björkholm, J. Koshiol, I. Turesson, and O. Landgren, “Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies,” Haematologica, vol. 94, no. 11, pp. 1581–1589, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori, “Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials,” Journal of the American Medical Association, vol. 295, no. 19, pp. 2275–2285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Wolfe and K. Michaud, “Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients,” Arthritis and Rheumatism, vol. 50, no. 6, pp. 1740–1751, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. E. F. Chakravarty, K. Michaud, and F. Wolfe, “Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors,” Journal of Rheumatology, vol. 32, no. 11, pp. 2130–2135, 2005. View at Scopus
  10. C. Weidler, P. Härle, J. Schedel, M. Schmidt, J. Schölmerich, and R. H. Straub, “Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens,” Journal of Rheumatology, vol. 31, no. 3, pp. 489–494, 2004. View at Scopus
  11. W. A. Khan, K. Alam, and M. Moinuddin, “Catechol-estrogen modified DNA: a better antigen for cancer autoantibody,” Archives of Biochemistry and Biophysics, vol. 465, no. 1, pp. 293–300, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. W. A. Khan, K. Alam, and Moinuddin, “Preferential recognition of catechol-estrogen modified DNA by circulating autoantibodies in cancer patients,” Biocimie, vol. 95, no. 1, pp. 329–335, 2013.
  13. R. H. Straub, “The complex role of estrogens in inflammation,” Endocrine Reviews, vol. 28, no. 5, pp. 521–574, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. R. Newbold and J. G. Liehr, “Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens,” Cancer Research, vol. 60, no. 2, pp. 235–237, 2000. View at Scopus
  15. J. G. Liehr, “Is estradiol a genotoxic mutagenic carcinogen?” Endocrine Reviews, vol. 21, no. 1, pp. 40–54, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. L. A. Suchar, R. L. Chang, R. T. Rosen, J. Lech, and A. H. Conney, “High-performance liquid chromatography separation of hydroxylated estradiol metabolites: formation of estradiol metabolites by liver microsomes from male and female rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 272, no. 1, pp. 197–206, 1995. View at Scopus
  17. A. R. Hoffman, S. M. Paul, and J. Axelrod, “The enzymatic formation of catecholestrogens from 2-methoxyestrogens by rat liver microsomes,” Endocrinology, vol. 107, no. 4, pp. 1192–1197, 1980. View at Scopus
  18. J. F. Strauss and R. L. Barbieri, Yen and Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, Elsevier Health Science, 6th edition, 2009.
  19. W. Yue, R. J. Santen, J.-P. Wang et al., “Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis,” Journal of Steroid Biochemistry and Molecular Biology, vol. 86, no. 3-5, pp. 477–486, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Dawling, N. Roodi, R. L. Mernaugh, X. Wang, and F. F. Parl, “Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms,” Cancer Research, vol. 61, no. 18, pp. 6716–6722, 2001. View at Scopus
  21. H. W. Deng and H. Shen, “Current topic in human genetics: studies in complex diseases,” in Genes in Oestrogen Metabolism Pathways and Breast Cancer, J. R. Long, Ed., p. 759, World Scientific Publishing, 2007.
  22. A. J. Lee, A. H. Conney, and B. T. Zhu, “Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16α-hydroxylation of estrone but not 17β-estradiol,” Cancer Research, vol. 63, no. 19, pp. 6532–6536, 2003. View at Scopus
  23. M. Gupta, A. McDougal, and S. Safe, “Estrogenic and antiestrogenic activities of 16α- and 2-hydroxy metabolites of 17β-estradiol in MCF-7 and T47D human breast cancer cells,” Journal of Steroid Biochemistry and Molecular Biology, vol. 67, no. 5-6, pp. 413–419, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. J. L. Bolton, E. Pisha, F. Zhang, and S. Qiu, “Role of quinoids in estrogen carcinogenesis,” Chemical Research in Toxicology, vol. 11, no. 10, pp. 1113–1127, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. H. L. Bradlow, D. W. Sepkovic, N. T. Telang, and M. P. Osborne, “Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent,” Annals of the New York Academy of Sciences, vol. 889, pp. 204–213, 1999. View at Scopus
  26. Z. Huang, F. P. Guengerich, and L. S. Kaminsky, “16α-Hydroxylation of estrone by human cytochrome P4503A4/5,” Carcinogenesis, vol. 19, no. 5, pp. 867–872, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Cavalieri, K. Frenkel, J. G. Liehr, E. Rogan, and D. Roy, “Estrogens as endogenous genotoxic agents—DNA adducts and mutations,” Journal of the National Cancer Institute. Monographs, no. 27, pp. 75–93, 2000. View at Scopus
  28. J. Embrechts, F. Lemière, W. Van Dongen et al., “Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry,” Journal of the American Society for Mass Spectrometry, vol. 14, no. 5, pp. 482–491, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Markushin, W. Zhong, E. L. Cavalieri et al., “Spectral characterization of catechol estrogen quinone (CEQ)-derived DNA adducts and their identification in human breast tissue extract,” Chemical Research in Toxicology, vol. 16, no. 9, pp. 1107–1117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. D. E. Stack, J. Byun, M. L. Gross, E. G. Rogan, and E. L. Cavalieri, “Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides,” Chemical Research in Toxicology, vol. 9, no. 5, pp. 851–859, 1996. View at Scopus
  31. K.-M. Li, R. Todorovic, P. Devanesan et al., “Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo,” Carcinogenesis, vol. 25, no. 2, pp. 289–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. K. M. Li, P. Davanson, E. G. Rogan, and E. L. Cavalieri, “Formation of the depurinating 4-hydroxyestradiol (4-OHE2)-1-N7 Gua and 4-OHE2-1-N3 Ade adducts by reaction of E2-3, 4-quinone with DNA,” in Proceeding for American Association of Cancer Research, p. 636, 1998.
  33. I. Terashima, N. Suzuki, and S. Shibutani, “Mutagenic properties of estrogen quinone-derived DNA adducts in Simian kidney cells,” Biochemistry, vol. 40, no. 1, pp. 166–172, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Chakravarti, P. C. Mailander, K.-M. Li et al., “Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene,” Oncogene, vol. 20, no. 55, pp. 7945–7953, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. J. G. Liehr, “Hormone-associated cancer: Mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters,” Environmental Health Perspectives, vol. 105, no. 3, pp. 565–569, 1997. View at Scopus
  36. M.-Y. Wang and J. G. Liehr, “Lipid hydroperoxide-induced endogenous DNA adducts in hamsters: Possible mechanism of lipid hydroperoxide-mediated carcinogenesis,” Archives of Biochemistry and Biophysics, vol. 316, no. 1, pp. 38–46, 1995. View at Publisher · View at Google Scholar · View at Scopus
  37. W. A. Khan and M. Moinuddin, “Binding characteristics of SLE anti-DNA autoantibodies to catecholestrogen-modified DNA,” Scandinavian Journal of Immunology, vol. 64, no. 6, pp. 677–683, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. W. A. Khan, S. Habib, W. A. Khan, K. Alam, and M. Moinuddin, “Enhanced binding of circulating SLE autoantibodies to catecholestrogen-copper-modified DNA,” Molecular and Cellular Biochemistry, vol. 315, no. 1-2, pp. 143–150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. W. A. Khan, M. Uddin, M. W. A. Khan, and H. S. Chabbra, “Catecholoestrogens: possible role in systemic lupus erythematosus,” Rheumatology, vol. 48, no. 11, pp. 1345–1351, 2009. View at Scopus
  40. W. A. Khan, M. Moinuddin, and A. S. Assiri, “Immunochemical studies on catechol-estrogen modified plasmid: possible role in rheumatoid arthritis,” Journal of Clinical Immunology, vol. 31, no. 1, pp. 22–29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Roy and J. G. Liehr, “Estrogen, DNA damage and mutations,” Mutation Research, vol. 424, no. 1-2, pp. 107–115, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Metzler, E. Pfeiffer, M. Schuler, and B. Rosenberg, “Effect of estrogen on microtubule assembly: significance for aneuploidy,” in Hormonal Carcinogenesis II, J. J. Li, S. Nandi, S. A. Li, J. Gustafasson, and L. Sekely, Eds., pp. 193–199, Spinger, New York, NY, USA, 1996.
  43. M. Cutolo, B. Villaggio, C. Craviotto, C. Pizzorni, B. Seriolo, and A. Sulli, “Sex hormones and rheumatoid arthritis,” Autoimmunity Reviews, vol. 1, no. 5, pp. 284–289, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Nalbandian and S. Kovats, “Estrogen, immunity & autoimmune disease,” Current Medicinal Chemistry, vol. 5, no. 1, pp. 85–91, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. L. A. Castagnetta, G. Carruba, O. M. Granata et al., “Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid asrthritis,” Journal of Rheumatology, vol. 30, no. 12, pp. 2597–2605, 2003. View at Scopus
  46. J. D. Yager and N. E. Davidson, “Estrogen carcinogenesis in breast cancer,” The New England Journal of Medicine, vol. 354, no. 3, pp. 228–282, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. R. K. Dubey, Y. Y. Tyurina, V. A. Tyurin et al., “Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth,” Circulation Research, vol. 84, no. 2, pp. 229–239, 1999. View at Scopus
  48. R. K. Dubey and E. K. Jackson, “Invited review: cardiovascular protective effects of 17β-estradiol metabolites,” Journal of Applied Physiology, vol. 91, no. 4, pp. 1868–1883, 2001. View at Scopus
  49. M. Folomeev, M. Dougados, J. Beaune et al., “Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus,” Lupus, vol. 1, no. 3, pp. 191–195, 1992. View at Scopus
  50. P. R. Kramer, S. F. Kramer, and G. Guan, “17β-estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages,” Arthritis and Rheumatism, vol. 50, no. 6, pp. 1967–1975, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Fotsis, Y. Zhang, M. S. Pepper et al., “The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth,” Nature, vol. 368, no. 6468, pp. 237–239, 1994. View at Publisher · View at Google Scholar · View at Scopus
  52. M. S. Cooke, N. Mistry, C. Wood, K. E. Herbert, and J. Lunec, “Immunogenicity of DNA damaged by reactive oxygen species—implications for anti-DNA antibodies in lupus,” Free Radical Biology and Medicine, vol. 22, no. 1-2, pp. 151–159, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Frenkel, J. Karkoszka, T. Glassman et al., “Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women,” Cancer Epidemiology Biomarkers and Prevention, vol. 7, no. 1, pp. 49–57, 1998. View at Scopus
  54. G. Jansson, “Oestrogen-induced enhancement of myeloperoxidase activity in human polymorphonuclear leukocytes—a possible cause of oxidative stress in inflammatory cells,” Free Radical Research Communications, vol. 14, no. 3, pp. 195–208, 1991. View at Scopus
  55. E. F. Chakravarty and M. C. Genovese, “Associations between rheumatoid arthritis and malignancy,” Rheumatic Disease Clinics of North America, vol. 30, no. 2, pp. 271–284, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Wolfe and K. Michaud, “Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients,” Arthritis and Rheumatism, vol. 50, no. 6, pp. 1740–1751, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Mellemkjær, M. S. Linet, G. Gridley, M. Frisch, H. Møller, and J. H. Olsen, “Rheumatoid arthritis and cancer risk,” European Journal of Cancer A, vol. 32, no. 10, pp. 1753–1757, 1996. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori, “Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials,” Journal of the American Medical Association, vol. 295, no. 19, pp. 2275–2285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Cutolo, “Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus,” Journal of Rheumatology, vol. 31, no. 3, pp. 419–421, 2004. View at Scopus
  60. B. Vandewalle and J. Lefebvre, “Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation,” Molecular and Cellular Endocrinology, vol. 61, no. 2, pp. 239–246, 1989. View at Scopus
  61. J. Fishman, J. Schneider, R. J. Hershcopf, and H. L. Bradlow, “Increased estrogen-16α-hydroxylase activity in women with breast and endometrial cancer,” Journal of Steroid Biochemistry, vol. 20, no. 4, part 2, pp. 1077–1081, 1984. View at Publisher · View at Google Scholar · View at Scopus
  62. N. T. Telang, A. Suto, G. Y. Wong, M. P. Osborne, and H. L. Bradlow, “Induction by estrogen metabolite 16α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells,” Journal of the National Cancer Institute, vol. 84, no. 8, pp. 634–638, 1992. View at Scopus
  63. J. Schneider, M. M. Huh, H. L. Bradlow, and J. Fishman, “Antiestrogen action of 2-hydroxyesterone on MCF-7 human breast cancer cells,” Journal of Biological Chemistry, vol. 259, no. 8, pp. 4840–4845, 1984. View at Scopus
  64. H. L. Bradlow, N. T. Telang, D. W. Sepkovic, and M. P. Osborne, “2-Hydroxyesterone: the “good” estrogen,” Journal of Endocrinology, vol. 150, pp. S259–S265, 1996. View at Scopus
  65. R. G. Lahita, H. L. Bradlow, H. G. Kunkel, and J. Fishman, “Alterations of estrogen metabolism in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 22, no. 11, pp. 1195–1198, 1979. View at Scopus
  66. M. R. Sowers, D. McConnell, M. Jannausch, A. G. Buyuktur, M. Hochberg, and D. A. Jamadar, “Estradiol and its metabolites and their association with knee osteoarthritis,” Arthritis and Rheumatism, vol. 54, no. 8, pp. 2481–2487, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. J. J. Li and S. A. Li, “Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism,” Federation Proceedings, vol. 46, no. 5, pp. 1858–1863, 1987. View at Scopus
  68. E. Cavalieri, E. Kohli, M. Zahid, and E. Rogan, “Greater reactivity of estradiol-3, 4-quinone vs estradiol-2, 3-quinone with DNA in the formation of depurinating DNA adducts,” Proceeding for American Association of Cancer Research, vol. 44, p. 180, 2003.
  69. E. G. Rogan, A. F. Badawi, P. D. Devanesan et al., “Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer,” Carcinogenesis, vol. 24, no. 4, pp. 697–702, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Cutolo, A. Sulli, and R. H. Straub, “Estrogen metabolism and autoimmunity,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A460–A464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Cutolo, “Hormone therapy in rheumatic diseases,” Current Opinion in Rheumatology, vol. 22, no. 3, pp. 257–263, 2010. View at Publisher · View at Google Scholar · View at Scopus